Table 1 Baseline patient characteristics
Variable | Apatinib (n = 40) | |
|---|---|---|
Median age (years) | 60 (39–71) | |
Gender | Male | 37 (92.5) |
Female | 3 (7.5) | |
ECOG performance status | 0 | 1 (2.5) |
1 | 38 (95.0) | |
2 | 1 (2.5) | |
Smoking status | Never | 4 (10) |
Former/current | 36 (90) | |
Stage (VALG) | Limited | 0 (0.0) |
Extensive | 40 (100.0) | |
Brain metastases | No | 33 (82.5) |
Yes | 7 (17.5) | |
Liver metastases | No | 16 (40.0) |
Yes | 24 (60.0) | |
Previous lines of treatment | 2 | 31 (77.5) |
3 | 9 (22.5) | |
Relapse type | Refractory | 17 (42.5) |
Sensitive | 23 (57.5) | |
Platinum re-challenge in second-line treatment | Yes | 27 (67.5) |
No | 13 (22.5) |
